Search research articles
Contact Us
Filters
Showing results (41-50 of 54) with videos related to
Page
of 6
Sort By:
Annals of the Rheumatic Diseases
|
July 15, 2005
Anti-serum amyloid component P antibodies in patients with systemic lupus erythematosus correlate with disease activity
G Zandman-Goddard, M Blank, P Langevitz, et al.
Annals of the Rheumatic Diseases
|
December 3, 2003
EULAR response criteria for polymyalgia rheumatica: results of an initiative of the European Collaborating Polymyalgia Rheumatica Group (subcommittee of ESCISIT)
B F Leeb, H A Bird, G Nesher, et al.
JIMD Reports
|
March 20, 2015
Investigating the Robustness and Diagnostic Potential of Extracellular Matrix Remodelling Biomarkers in Alkaptonuria
F Genovese, A S Siebuhr, K Musa, et al.
Scientific Reports
|
July 13, 2019
Quantification of the flux of tyrosine pathway metabolites during nitisinone treatment of Alkaptonuria
A M Milan, A T Hughes, A S Davison, et al.
Lupus
|
July 8, 2010
Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study
J Zavada, Ss Pesickova, R Rysava, et al.
Lupus
|
November 12, 2013
Extended follow-up of the CYCLOFA-LUNE trial comparing two sequential induction and maintenance treatment regimens for proliferative lupus nephritis based either on cyclophosphamide or on cyclosporine A
J Závada, S Sinikka Pesicková, R Rysavá, et al.
Annals of the Rheumatic Diseases
|
May 5, 2010
Serum concentrations of 25-OH vitamin D in patients with systemic lupus erythematosus (SLE) are inversely related to disease activity: is it time to routinely supplement patients with SLE with vitamin D?
H Amital, Z Szekanecz, G Szücs, et al.
Molecular Genetics and Metabolism Reports
|
March 4, 2022
Characterization of changes in the tyrosine pathway by 24-h profiling during nitisinone treatment in alkaptonuria
L R Ranganath, A M Milan, A T Hughes, et al.
Osteoarthritis and Cartilage
|
June 1, 2018
Inflammatory and oxidative stress biomarkers in alkaptonuria: data from the DevelopAKUre project
D Braconi, D Giustarini, B Marzocchi, et al.
Annals of the Rheumatic Diseases
|
July 23, 2013
EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases
N Duru, M C van der Goes, J W G Jacobs, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 54) with videos related to
Sort By:
Page
of 6
Annals of the Rheumatic Diseases
|
July 15, 2005
Anti-serum amyloid component P antibodies in patients with systemic lupus erythematosus correlate with disease activity
G Zandman-Goddard, M Blank, P Langevitz, et al.
Annals of the Rheumatic Diseases
|
December 3, 2003
EULAR response criteria for polymyalgia rheumatica: results of an initiative of the European Collaborating Polymyalgia Rheumatica Group (subcommittee of ESCISIT)
B F Leeb, H A Bird, G Nesher, et al.
JIMD Reports
|
March 20, 2015
Investigating the Robustness and Diagnostic Potential of Extracellular Matrix Remodelling Biomarkers in Alkaptonuria
F Genovese, A S Siebuhr, K Musa, et al.
Scientific Reports
|
July 13, 2019
Quantification of the flux of tyrosine pathway metabolites during nitisinone treatment of Alkaptonuria
A M Milan, A T Hughes, A S Davison, et al.
Lupus
|
July 8, 2010
Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study
J Zavada, Ss Pesickova, R Rysava, et al.
Lupus
|
November 12, 2013
Extended follow-up of the CYCLOFA-LUNE trial comparing two sequential induction and maintenance treatment regimens for proliferative lupus nephritis based either on cyclophosphamide or on cyclosporine A
J Závada, S Sinikka Pesicková, R Rysavá, et al.
Annals of the Rheumatic Diseases
|
May 5, 2010
Serum concentrations of 25-OH vitamin D in patients with systemic lupus erythematosus (SLE) are inversely related to disease activity: is it time to routinely supplement patients with SLE with vitamin D?
H Amital, Z Szekanecz, G Szücs, et al.
Molecular Genetics and Metabolism Reports
|
March 4, 2022
Characterization of changes in the tyrosine pathway by 24-h profiling during nitisinone treatment in alkaptonuria
L R Ranganath, A M Milan, A T Hughes, et al.
Osteoarthritis and Cartilage
|
June 1, 2018
Inflammatory and oxidative stress biomarkers in alkaptonuria: data from the DevelopAKUre project
D Braconi, D Giustarini, B Marzocchi, et al.
Annals of the Rheumatic Diseases
|
July 23, 2013
EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases
N Duru, M C van der Goes, J W G Jacobs, et al.
Page
of 6